YU36900A - Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan - Google Patents
Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendanInfo
- Publication number
- YU36900A YU36900A YU36900A YU36900A YU36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- levosimendan
- patient
- source
- mucous membrane
- transmucosal formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Abstract
Opisan je intraoralni ili intranazalni transmukozni preparat koji sadrži levosimendan ili njegovu farmaceutski prihvatljivu so kao aktivnu komponentu. Ovaj preparat je bukalni, sublingualni ili sinuidalni transmukozni preparat. Opisana je upotreba ovog preparata za proizvodnju medikamenta - leka za transmukoznu primenu oralne ili nazalne mukoze za tretiranje srčanog udara.[Described is a method of administering transmucosally, particularly to oral or nasal mucosa, levosimendan or a pharmaceutically acceptable salt thereof to a patient. The method comprises contacting an intact mucous membrane with a source of levosimendan, and maintaining said source in contact with said mucous membrane for a sufficient time period to deliver levosimendan to the patient. Transmucosal preparations of levosimendan are also described. Levosimendan is useful in the treatment of heart failure.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI974578A FI974578A (fi) | 1997-12-19 | 1997-12-19 | Menetelmä levosimendaanin antamiseksi |
Publications (2)
Publication Number | Publication Date |
---|---|
YU36900A true YU36900A (sh) | 2003-02-28 |
RS49889B RS49889B (sr) | 2008-08-07 |
Family
ID=8550178
Country Status (26)
Country | Link |
---|---|
US (1) | US6399610B1 (sh) |
EP (1) | EP1052973B1 (sh) |
JP (1) | JP2001526205A (sh) |
KR (1) | KR100753689B1 (sh) |
AT (1) | ATE215358T1 (sh) |
AU (1) | AU738082B2 (sh) |
BR (1) | BR9813641A (sh) |
CA (1) | CA2313618C (sh) |
CZ (1) | CZ296693B6 (sh) |
DE (1) | DE69804678T2 (sh) |
DK (1) | DK1052973T3 (sh) |
EA (1) | EA002197B1 (sh) |
EE (1) | EE04330B1 (sh) |
ES (1) | ES2175827T3 (sh) |
FI (1) | FI974578A (sh) |
HR (1) | HRP20000400B1 (sh) |
HU (1) | HU226736B1 (sh) |
IL (1) | IL136415A (sh) |
NO (1) | NO320050B1 (sh) |
NZ (1) | NZ504806A (sh) |
PL (1) | PL191868B1 (sh) |
PT (1) | PT1052973E (sh) |
RS (1) | RS49889B (sh) |
SK (1) | SK284838B6 (sh) |
WO (1) | WO1999032081A1 (sh) |
ZA (1) | ZA9811405B (sh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI980901A (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaania säädellysti vapauttavia oraalisia koostumuksia |
FI20002755A0 (fi) | 2000-12-15 | 2000-12-15 | Orion Yhtymae Oyj | Menetelmä erektiilin dysfunktion hoitamiseen |
CN100428937C (zh) * | 2003-10-30 | 2008-10-29 | 北京海合天科技开发有限公司 | 左西孟旦冷冻干燥组合物 |
FI20040674A0 (fi) * | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
EP1848270B1 (en) * | 2005-02-17 | 2014-05-21 | Abbott Laboratories | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
CA2596768A1 (en) * | 2005-02-18 | 2006-08-24 | Orion Corporation | A method for treating heart failure |
WO2007096906A2 (en) * | 2006-02-27 | 2007-08-30 | Panacea Biotec Ltd. | Novel buccoadhesive compositions and process of preparation thereof |
CN101516426A (zh) * | 2006-09-27 | 2009-08-26 | 尼克诺姆股份公司 | 定向用途 |
EP3941450A4 (en) * | 2019-03-22 | 2022-12-21 | Dbbh, Llc | INTRANASAL ANTIHISTAMINES AND ASSOCIATED USES |
WO2021001601A1 (en) * | 2019-07-01 | 2021-01-07 | Orion Corporation | Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide |
CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
US5688520A (en) * | 1995-03-29 | 1997-11-18 | Minnesota Mining And Manufacturing Company | Transmucosal delivery of melatonin for prevention of migraine |
GB9614098D0 (en) | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
-
1997
- 1997-12-19 FI FI974578A patent/FI974578A/fi unknown
-
1998
- 1998-12-11 JP JP2000525076A patent/JP2001526205A/ja active Pending
- 1998-12-11 EP EP98959930A patent/EP1052973B1/en not_active Expired - Lifetime
- 1998-12-11 US US09/581,610 patent/US6399610B1/en not_active Expired - Fee Related
- 1998-12-11 ES ES98959930T patent/ES2175827T3/es not_active Expired - Lifetime
- 1998-12-11 ZA ZA9811405A patent/ZA9811405B/xx unknown
- 1998-12-11 AT AT98959930T patent/ATE215358T1/de not_active IP Right Cessation
- 1998-12-11 AU AU15656/99A patent/AU738082B2/en not_active Ceased
- 1998-12-11 DE DE69804678T patent/DE69804678T2/de not_active Expired - Lifetime
- 1998-12-11 CA CA002313618A patent/CA2313618C/en not_active Expired - Fee Related
- 1998-12-11 CZ CZ20002155A patent/CZ296693B6/cs not_active IP Right Cessation
- 1998-12-11 PT PT98959930T patent/PT1052973E/pt unknown
- 1998-12-11 EE EEP200000368A patent/EE04330B1/xx not_active IP Right Cessation
- 1998-12-11 NZ NZ504806A patent/NZ504806A/en unknown
- 1998-12-11 HU HU0100452A patent/HU226736B1/hu not_active IP Right Cessation
- 1998-12-11 PL PL341202A patent/PL191868B1/pl not_active IP Right Cessation
- 1998-12-11 EA EA200000686A patent/EA002197B1/ru not_active IP Right Cessation
- 1998-12-11 DK DK98959930T patent/DK1052973T3/da active
- 1998-12-11 BR BR9813641-0A patent/BR9813641A/pt not_active Application Discontinuation
- 1998-12-11 KR KR1020007006835A patent/KR100753689B1/ko not_active IP Right Cessation
- 1998-12-11 RS YUP-369/00A patent/RS49889B/sr unknown
- 1998-12-11 WO PCT/FI1998/000977 patent/WO1999032081A1/en active IP Right Grant
- 1998-12-11 SK SK906-2000A patent/SK284838B6/sk not_active IP Right Cessation
- 1998-12-11 IL IL13641598A patent/IL136415A/xx not_active IP Right Cessation
-
2000
- 2000-06-14 NO NO20003059A patent/NO320050B1/no not_active IP Right Cessation
- 2000-06-16 HR HR20000400A patent/HRP20000400B1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU1079701A (en) | Oral transmucosal drug dosage using solid solution | |
KR970703151A (ko) | 알렌드로네이트의 경구 액상 제형(Oral liquid alendronate formulations) | |
EP1033998A4 (en) | METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER | |
WO1998035658A3 (de) | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon | |
YU36900A (sh) | Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan | |
PL335561A1 (en) | Application of levobupivacaine in face surgery | |
GR3034665T3 (en) | Antitussive composition containing an antitussive and benzydamine | |
MY114716A (en) | Prophylactic and/or therapeutic treatment of dyspeptic symptoms | |
MD1469G2 (ro) | Metodă de tratament al şocului combustional | |
RU97115801A (ru) | Способ лечения стенозирующих ларинготрахеитов у детей | |
UA35948A (uk) | Спосіб профілактики уражень слизової оболонки порожнини рота і губ | |
MY117556A (en) | Methods and formulations for modulating the human sexual response | |
UA35918A (uk) | Спосіб лікування червоного плескатого лишаю слизової оболонки порожнини рота |